http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110352058-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5a311ab782d8a45b3867a834ab6c93 |
| publicationDate | 2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110352058-A |
| titleOfInvention | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
| abstract | Applicants provide methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of glucocorticoid receptor modulators (GRMs) and steroidogenesis inhibitors, and concomitant administration of GRMs and CYP3A inhibitors. A GRM can be, for example, mifepristone; a CYP3A inhibitor or steroidogenesis inhibitor (collectively "inhibitors") can be, for example, ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions; concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to inhibitors and/or other drugs. Applicants have surprisingly found that GRM can be administered to subjects who are receiving inhibitors without increasing the risk of adverse reactions; for example, Applicants have found that mifepristone can be administered concomitantly with ketoconazole or itraconazole, providing GRM and ketoconazole Safe concomitant administration of azole or itraconazole. In embodiments, the GRM dose may be reduced during concomitant administration of the GRM and inhibitor. |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 373.